AQST

Aquestive Therapeutics, Inc. (AQST) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Aquestive Therapeutics is a pharmaceutical company focused on developing medicines using innovative delivery technologies, primarily for severe allergic reactions (Anaphylm) and CNS disorders (Libervant). The company operates as a single segment, serving as the exclusive manufacturer for its licensed products and advancing its proprietary pipeline. As of September 30, 2025, the company had 121,658,113 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue margins are not applicable as the company operates at a loss. Gross profit is not explicitly stated, but Cost of Manufacture and Supply was $4.5M for Q3 2025.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 5% in Q3 2025 and 31% in the nine months ended September 30, 2025, compared to the prior year.
  • License and Royalty Revenue: Dropped 52% in Q3 and 82% in the 9M period. This is primarily due to the one-time recognition of deferred revenue in 2024 resulting from the termination of licensing agreements (Haisco and MTPA).
  • Proprietary Product Revenue: Decreased to zero in Q3 2025 due to the cessation of U.S. market access for Libervant following a court ruling in February 2025.
  • Manufacture and Supply: Increased 7% in Q3 2025 (driven by Sympazan and Suboxone) but decreased 4% in the 9M period (driven by a decline in Suboxone volumes).
• Expense Increases: Selling, General, and Administrative (SG&A) expenses increased 26% in Q3 and 38% in the 9M period. This was driven by commercial spending in preparation for the Anaphylm launch, higher legal fees, and regulatory expenses.
  • R&D Expenses: Decreased 14% in Q3 and 9% in the 9M period, largely due to lower clinical trial costs for Anaphylm, partially offset by increased share-based compensation due to severance.
• Liquidity Improvement: Cash and cash equivalents increased to $129.1M from $71.5M at year-end 2024, bolstered by a $79.9M underwritten public offering in August 2025 and ATM facility sales.

Guidance, Outlook, and Risks

• Anaphylm Outlook: The company submitted a New Drug Application (NDA) for Anaphylm in Q1 2025. The FDA accepted the submission with a PDUFA target action date of January 31, 2026. The company plans to launch in Q1 2026 if approved. The FDA confirmed an advisory committee meeting is not required.
• Libervant Status: U.S. market access for Libervant (ages 2-5) was vacated by a District Court ruling in February 2025. The FDA converted the approval to "tentative," and the company has ceased U.S. marketing. The FDA is appealing the ruling. Market access remains blocked until the Orphan Drug Exclusivity (ODE) for a competitor expires in January 2027 or the ruling is overturned.
• Liquidity and Funding: Management states that existing cash, expense management, and access to equity markets (including a remaining $78M ATM capacity) provide liquidity for at least the next 12 months.
  • Debt Obligations: The company has $45M in 13.5% Senior Secured Notes due 2028. Principal amortization payments begin in June 2026.
  • RTW Agreement: Entered into a purchase agreement with RTW Investments LP for $75M, contingent on Anaphylm FDA approval by a specified date and debt refinancing.
• Risks:
  • Regulatory Risk: Potential delays in FDA approval of Anaphylm due to government shutdowns or additional data requests.
  • Legal Risk: Ongoing litigation regarding Libervant approval and Suboxone product liability (dental injuries) in MDL and Canadian class actions.
  • Revenue Concentration: Significant reliance on Indivior (Suboxone) and Hypera (Ondif), which represented 72% and 18% of revenue, respectively, in the first nine months of 2025.

Investor Verification Checklist

• Anaphylm Approval Timeline: Verify the status of the NDA review and confirm the January 31, 2026 PDUFA date remains unchanged.
• Libervant Litigation: Monitor the appeal process of the District Court ruling vacating Libervant's approval and the FDA's response to the company's request for clinical superiority determination.
• Cash Burn Rate: Assess the sustainability of the $129M cash balance against the projected operating losses and upcoming debt principal payments starting in 2026.
• RTW Deal Conditions: Confirm the specific "specified date" for Anaphylm approval required to trigger the $75M payment from RTW Investments.
• Suboxone Market Share: Evaluate the impact of generic competition on Suboxone film market share (currently ~25%) and future revenue projections.